FDA expands essential thrombocythemia care - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA expands essential thrombocythemia care

Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.

  • By

  • Kathryn Wighton

  • September 1, 2026

  • 2 min

Share

Clinical Scorecard: FDA expands essential thrombocythemia care

At a Glance

CategoryDetail
ConditionEssential Thrombocythemia
Key MechanismsOverproduction of platelets in the bone marrow
Target PopulationAdults with essential thrombocythemia, including newly diagnosed patients
Care SettingOncology and hematology clinics

Key Highlights

  • FDA approved ropeginterferon alfa-2b-njft for essential thrombocythemia treatment
  • First new treatment for ET in nearly 30 years
  • Higher durable response rates compared to anagrelide
  • Treatment reduces thromboembolic events over 12 months
  • Boxed warning for potential severe side effects

Guideline-Based Recommendations

Diagnosis

  • Diagnosis based on clinical criteria and laboratory findings

Management

  • Ropeginterferon alfa-2b-njft as a treatment option for ET

Monitoring & Follow-up

  • Monitor for neuropsychiatric, autoimmune, ischemic, and infectious disorders

Risks

  • Increased risk of blood clots, abnormal bleeding, and complications such as heart attack and stroke

Patient & Prescribing Data

Adults with essential thrombocythemia

Ropeginterferon alfa-2b-njft targets disease-driving bone marrow cells

Clinical Best Practices

  • Consider patient history for contraindications before prescribing
  • Monitor platelet counts and overall disease burden during treatment

Related Resources & Content

Original Source(s)

FDA expands essential thrombocythemia care

  • by Kathryn Wighton

  • September 1, 2026

Related Content

Hinoki root oil may reduce nighttime wakefulness

Women exposed to Japanese cypress root volatiles for 13 days reported less morning sleepiness and better fatigue recovery in a small crossover study.

Nirsevimab may curb RSV severity

Real-world estimates showed protection across emergency, inpatient, and intensive care settings during Canada’s first universal immunization season.

Lasers trigger pigmentation from past gold therapy

Short-pulse lasers triggered chrysiasis more than 30 years after treatment in 2 patients with rheumatoid arthritis.